Bone health
MBP® is a whey protein fraction supported by mechanistic and clinical studies demonstrating its efficacy in reinforcing bone mineral density for women of all ages. 40 mg/day.
MBP® - Key features
-
Inhibits bone resorption through cysteine protease inhibition
-
Clinically proven to increase bone mineral density by inhibiting bone resorption
-
Bone homeostasis is significantly improved after 3 months
-
Bone mineral density increases significantly after 6 months
Science supporting MBP®
Several clinical studies are supporting the benefits of MBP® on bone mineral density support. Double-blind, randomized, and placebo-controlled, these studies are designed to study different populations of women of all ages from younger age to post-menopause.
More than 10 articles supporting the mechanism of action and health benefits of MBP® have been published.
Characterisation
MBP is a coproduct of the manufacturing of lactoferrin, obtained by chromatography on ion exchange resin and being released at basic pH, Milk Basic Protein.
Bioactive compounds
Protein content ≥ 93%
incl. Lactoferrin 45%-60%
CPI activity ≥ 22 mU/mg
Composition: Whey fraction from skimmed cow milk
Recommended daily dosage: 40 mg
Mechanism of action
The bone is dynamically regulated through continuous processes of bone formation, driven by osteoblasts, and bone resorption, facilitated by osteoclasts. Simultaneously, these two processes maintain bone homeostasis, contributing to overall bone health and mineral density.
MBP® is demonstrated to promote bone formation and inhibit bone resorption.
Mechanistic studies showed that MBP promotes the growth of osteoblasts and the synthesis of collagen in vitro. In women of all ages, the supplementation of MBP reduces the biomarkers of bone resorption.
Clinically supported benefits
Double-blind, randomised, placebo-controlled studies.
| LOCATIONS |
Japan Kagawa Nutrition University |
Japan Kagawa Nutrition University |
Japan Kagawa Nutrition University |
Japan Kagawa Nutrition University |
| YEAR & DURATION | 2007 6 months |
2001 6 months |
2005 6 months |
2010 12 months |
| POPULATIONS |
20-23 years old
|
20-37 years old
|
20-23 years old Onset menopause |
65-86 years old Post-menopause |
| INTAKES |
40 mg/day in 50 ml of water |
40 mg/day in 50 ml of water | 40 mg/day in 50 ml of water | 40 mg/day in 50 ml of water |
PROTOCOLS:
- Measure of blood and urine biomarkers of bone metabolism
- Measure of bone mineral density by DXA scan
- Usual diet
- No supplementation in vitamin D or calcium
MBP® increases spine bone mineral density in 6 months.
The direct impact of the consumption of MBP on bone mineral density is proven in the clinical studies, highlighting the results in increase of bone mineral density on a site of reference, the section L2-L4 of the lumbar spine, often used to study osteoporosis development. The supplementation with 40 mg of MPB per day for 6 months resulted in a significant increase of +1.44% in young (20s) and +1.87% in women at the onset of menopause.
The impact of MBP is not only reported in the spine. MBP also increases the bone mineral density of other bones. The 33 women aged 28.8 ± 8.7 years significantly improved radial and calcaneal bone mineral density.
MBP® is safe
No adverse event linked to MBP® supplementation has been recorded.
Regulatory & Certifications
Non-GMO, Halal, Kosher, gluten-free, suitable for vegetarians.
GRAS status - Notice No. GRN 000196
Japanese FOSHU registration 1276: "This product with MBP, which is effective to increase bone density, is suitable for people conscious of bone health"
South Korea Health Ingredient registration 2015-16: "May help to maintain healthy bone"
Australia / New Zealand - Claims available for food products: maintenance of normal bones/healthy bones // maintenance of bone mineralisation // maintenance of bone mineral density
References
MECHANISTIC STUDIES
Takada et al.; BBRC; 1995
Takada et al.; Int. Dairy Journal; 1997
Yamamura et al; BBRC; 1999
Yamamura et al.; BBRC; 2000
Takada et al.; Nutr. Aspec. Osteoporosis; 2001
Toba et al;Bone; 2001
Matsuoka et al.; Biosci. Biotechnol. Biochem.; 2002
CLINICAL TRIALS
Aoe et al; Osteoporosis Int; 2005
Uenishi et al; Osteoporosis Int; 2007
Aoe et al; Biosci. Biotechnol. Biochem; 2001
Yamamura et al; Biosci. Biotechnol. Biochem; 2002
This website is intended to provide information about Fytexia’s ingredients, used in various food/dietary supplement products around the world. It is only intended for business to business and to provide information to food/dietary supplement professionals and is not designed for the general public. Statements used on this website have not been evaluated by the Food and Drug Administration or any other competent authority. Products are not intended to diagnose, treat, cure or prevent any disease.
